Peachtree Investment Advisors’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2018
Q4
$327K Hold
3,545
0.25% 61
2018
Q3
$335K Hold
3,545
0.23% 64
2018
Q2
$328K Buy
3,545
+250
+8% +$24.4K 0.24% 62
2018
Q1
$312K Sell
3,295
-365
-10% -$40.1K 0.23% 65
2017
Q4
$354K Hold
3,660
0.27% 67
2017
Q3
$325K Sell
3,660
-1,300
-26% -$99K 0.28% 67
2017
Q2
$360K Buy
4,960
+1,300
+36% +$87.4K 0.31% 63
2017
Q1
$238K Hold
3,660
0.22% 79
2016
Q4
$229K Hold
3,660
0.22% 86
2016
Q3
$231K Sell
3,660
-2,276
-38% -$147K 0.23% 81
2016
Q2
$367K Hold
5,936
0.37% 66
2016
Q1
$339K Hold
5,936
0.34% 72
2015
Q4
$352K Sell
5,936
-1,600
-21% -$92.2K 0.37% 69
2015
Q3
$410K Hold
7,536
0.43% 63
2015
Q2
$506K Hold
7,536
0.38% 71
2015
Q1
$441K Buy
7,536
+700
+10% +$42.3K 0.32% 80
2014
Q4
$447K Hold
6,836
0.3% 91
2014
Q3
$395K Sell
6,836
-180
-3% -$9.99K 0.26% 96
2014
Q2
$396K Sell
7,016
-1,390
-17% -$72.9K 0.26% 92
2014
Q1
$432K Hold
8,406
0.29% 91
2013
Q4
$444K Buy
+8,406
New +$413K 0.3% 90

Other funds holding ABBV

Peachtree Investment Advisors's ABBV Position: Q4 2018 in Review

Peachtree Investment Advisors held its AbbVie (ABBV) position steady in Q4 2018 at 3,545 shares worth $327K. The position accounts for 0.25% of the portfolio, ranked #61.

Peachtree Investment Advisors first reported a position in ABBV in Q4 2013 and has held it in 21 quarters since. The position peaked at $506K in Q2 2015. 2,063 funds tracked by Wall St. Rank hold ABBV as of Q4 2018.

  • Peachtree Investment Advisors held 3,545 shares of AbbVie worth $327K as of Q4 2018.
  • Peachtree Investment Advisors left its AbbVie share count unchanged in Q4 2018.
  • AbbVie made up 0.25% of Peachtree Investment Advisors's portfolio in Q4 2018, its #61 holding.
  • Peachtree Investment Advisors first reported a position in AbbVie in Q4 2013 and has held it in 21 quarters since.
  • Peachtree Investment Advisors's AbbVie position peaked at $506K in Q2 2015.
  • 2,063 funds tracked by Wall St. Rank held AbbVie as of Q4 2018.

Based on Peachtree Investment Advisors's 13F filing for Q4 2018, filed 14 Jan 2019.